atezolizumab,cabozantinib
roche,exelixis
['lcsm,(-blcsm)', 'nsclc', 'cabozantinib', 'cosmic-021', 'atezo', 'sclc']
#asco22 news: findings from the multicohort cosmic-021 study highlight the potential of cabozantinib plus atezolizumab for ici-treated patients with advanced nsclc. presented by of #lcsm 
Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology.